Prospective Bi-Centric Real-World Outcomes of Upadacitinib in Biologic-Experienced Patients with Crohn’s Disease
Upadacitinib demonstrates significant clinical and endoscopic efficacy in biologic-experienced, anti-TNF-pretreated patients with CD, achieving remission rates comparable to or exceeding those of the pivotal trials despite a highly refractory population (75% with ≥3 prior biologic failures). The favorable safety profile supports upadacitinib as an important therapeutic option in sequential treatment of refractory CD.
Authors
- Arne Bokemeyer (ORCID: https://orcid.org/0000-0002-4238-751X)
- Joost Buskermolen
- C. L. Zippel
- Tina Schomacher
- P R Tepasse
- Richard Vollenberg
- Janina Lüke
- Frank Lenze
- Markus Strauss
- Julia Fischer
Institutions
- Witten/Herdecke University (DE)
- University Hospital Münster (DE)
- Hochtemperatur-Kernkraftwerk (Germany) (DE)
- St. Bonifatius Hospital (DE)
Publication Details
- Journal
- Diseases
- Published
- 2026-02-01
- DOI
- https://doi.org/10.3390/diseases14020054
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00